Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial - Top-Institutions - MDSpire

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

  • By

  • Chengshui Chen

  • Xinyu Liang

  • Zheng Peng

  • Yan Zou

  • Huijuan He

  • Xiaoyan Zhang

  • Yi He

  • Shixiu Wu

  • May 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Quzhou People’s Hospital
    Quzhou People’s Hospital

    Quzhou, Zhejiang

    Key Differentiators

    • Dermatology

  • #2

    National Cancer Institute
    National Cancer Institute

    Bethesda, Maryland

    Key Differentiators

    • Oncology
    • Dermatology

  • #3

    European Organisation for Research and Treatment of Cancer
    European Organisation for Research and Treatment of Cancer

    Brussels, Brussels-Capital Region

    Key Differentiators

    • Oncology
    • Dermatology

Original Source(s)

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

  • by Chengshui Chen, Xinyu Liang, Zheng Peng, Yan Zou, Huijuan He, Xiaoyan Zhang, Yi He, Shixiu Wu

  • May 1, 2026

Related Content

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer